🔎 Trials Near Me

Home › Interstitial Lung Diseases › Florida › Jacksonville

Interstitial Lung Diseases clinical trials in Jacksonville, FL

5 studies for Interstitial Lung Diseases are looking for participants at sites in and around Jacksonville (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

RecruitingPhase 2/3
  • GSK Investigational Site, Jacksonville
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

RecruitingPhase 2/3
  • Mayo Clinic Florida, Jacksonville
Ages 18 to 75 · All sexes · Updated Aug 17, 2026 · NCT06328777

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

RecruitingPhase 2
  • Mayo Clinic of Florida, Jacksonville
Ages 18 to 80 · All sexes · Updated Aug 10, 2026 · NCT07175038

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

RecruitingPhase 3
  • Ascension Medical Group St. Vincent's Lung Institute, Jacksonville
  • Mayo Clinic, Jacksonville
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535

Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease

Recruiting
  • Mayo Clinic in Florida, Jacksonville
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT06751069

About Interstitial Lung Diseases

Interstitial lung diseases are a group of diseases that inflame or scar the lungs. Breathing in particles (asbestosis, silicosis) causes some types.

More about Interstitial Lung Diseases on MedlinePlus

Interstitial Lung Diseases trials in other cities

Other studies in Jacksonville

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.